Jeremie Calais

LUNAR update in Eur Urol, +10 mo follow-up (median 31.9 mo)

177Lu-PSMA + SBRT vs SBRT, oligorecurrent HSPC:
▸ Polymetastatic PFS (PCWG4) HR 0.28, p=0.04
▸ HT-free survival HR 0.57, p=0.03
▸ CT-based PFS HR 0.46, p=0.07
▸ PSMA PET PFS HR 0.38, p<0.001

doi.org/10.1016/j.euru…

Goodbye L.A. Bonjour Paris ! After 10 years in Los Angeles at @UCLA, a new chapter in life begins for me: I'm back in Paris. On September 1st, I take a new position as Professor at Institut @GustaveRoussy, Université Paris-Saclay, @UnivParisSaclay

Final dosimetry analysis of RESIST-PC: the first prospective US ¹⁷⁷Lu-PSMA trial (2017).
→ No absorbed doses difference between 6.0 vs 7.4 GBq
→ Wide tumor dose variability
→ Hybrid planar + SPECT protocol is suboptimal and should not be used anymore
jnm.snmjournals.org/content/early/…

LPS-Boost: a multicenter Phase 2 trial testing individualized & intensified ¹⁷⁷Lu-PSMA therapy.
🎯 PSMA PET selection of low PSMA-expressing disease
⚡ Paired administrations 1 week apart
Protocol now in @JournalofNucMed
jnm.snmjournals.org/content/early/…

#ASCO26 (Chicago) & #SNMMI26 (LA) overlapped entirely this year. I was invited to speak at both, and I attended both.✈️
Organizers: please don't do this again. #Theranostics needs #MedicalOncology and #NuclearMedicine in the same room, not 3000 km apart.